Dalazatide

Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease[1][2][3].

Product Specifications

CAS Number

[1081110-69-1]

Product Name Alternative

ShK-186

UNSPSC

12352209

Target

Potassium Channel

Type

Peptides

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dalazatide.html

Purity

99.23

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

CC[C@@H]([C@@H]1NC([C@@H](NC([C@@H](NC([C@@](OCCOCCN)(N(C([C@H](Cc2ccc(OP(O)(O)=O)cc2)N)=O)C(C)=O)CCCNC(N)=N)=O)CO)=O)CSSC[C@@H](C(N)=O)NC([C@H]([C@H](O)C)NC(CNC(C3CSSC[C@@H]4NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]5CCCN5C([C@H]([C@H](CC)C)NC([C@H]([C@H](O)C)NC([C@@H](NC1=O)CC(O)=O)=O)=O)=O)=O)CCCCN)=O)CO)=O)CCCNC(N)=N)=O)CSSC[C@@H](C(NC(C(NC(C(N[C@H](C(N3)=O)[C@H](O)C)=O)CCCCN)=O)CCCNC(N)=N)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC4=O)CCCCN)=O)Cc6nc[nH]c6)=O)CO)=O)CCSC)=O)CCCCN)=O)Cc7ccc(O)cc7)=O)CCCNC(N)=N)=O)CC(C)C)=O)CO)=O)Cc8ccccc8)=O)=O)=O)C)=O)Cc9ccccc9)=O)CCC(N)=O)=O)=O)=O)=O)=O)C

Molecular Formula

C184H296N57O55PS7

Molecular Weight

4442.10

References & Citations

[1]Olsen C, et al. Dalazatide (ShK-186), a first-in-class peptide inhibitor of Kv1. 3 potassium channels, demonstrates safety, tolerability and proof of concept of efficacy in patients with active plaque psoriasis. J. Invest. Dermatol., 2016, 136 (8) . |[2]Stevens A M, et al. Thu0285 Dalazatide, an Inhibitor of the KV1. 3 Channel on Activated Effector Memory T Cells, Has Immunotherapy Potential in Systemic Lupus Erythematosus. 2016. |[3]Matheu MP, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17;29 (4) :602-14.